论文部分内容阅读
研究了４２例骨髓增生异常综合征患者体外ＣＦＵ－ＧＭ、ＣＦＵ－Ｌ培养和细胞遗传学改变。结果显示，患者ＣＦＵ－ＧＭ明显低于正常对照组（Ｐ＜０．０１），但高于再生障碍性贫血（ＡＡ）（Ｐ＜０．０１），ＣＦＵ－Ｌ高于正常对照组和ＡＡ组（Ｐ＜０．０１）。患者５２．４％存在染色体异常，常见为：＋８、－２２、－Ｘ、－Ｙ、－２０、－７／７ｑ－。ＣＦＵ－ＧＭ减低、ＣＦＵ－Ｌ增高和染色体异常者疗效较正常者差。表明ＣＦＵ－ＧＭ、ＣＦＵ－Ｌ体外培养和细胞遗传学检查可作为ＭＤＳ协助诊断和预测疗效的指标之一。
The CFU-GM, CFU-L culture and cytogenetic changes in 42 patients with myelodysplastic syndrome were studied in vitro. The results showed that patients with CFU-GM were significantly lower than the normal control group (P <0.01), but higher than the aplastic anemia (AA) (P <0.01), CFU-L was higher than the normal control group and AA group (P<0.01). There are chromosomal abnormalities in 52.4% of the patients, which are usually: +8, -22, -X, -Y, -20, -7/7q-. CFU-GM decreased, CFU-L increased and chromosomal abnormalities were worse than normal. It was shown that the CFU-GM, CFU-L in vitro culture and cytogenetic examination can be used as one of the indicators of MDS assisted diagnosis and prediction of efficacy.